期刊
NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 4, 页码 261-278出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4505
关键词
-
资金
- Canadian Institutes for Health Research (CIHR) Fellowship for Health Professionals
- Vanier Canada Graduate Scholarship
- CIHR grants [MOP-106530, MOP-115126]
- Susan G. Komen Breast Cancer Foundation [IIR12224057]
- CIHR [MOP-7214, MOP-115195]
- Canadian Cancer Society Research Institute [702317]
- Howard Hughes Medical Institute [55007654]
- Cancer Research Society operating grant
- Swedish Foundation for International Cooperation in Research and Higher Education
- CIHR Young Investigator Award
- Fonds de Recherche du Quebec-Sante
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据